Effectiveness of Midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial)

Europace

Volumn 13, Issue 11, 2011, Pages 1639-1647

  Romme, Jacobus J C M ^a   Van Dijk, Nynke ^a   Go Schön, Ingeborg K ^a   Reitsma, Johannes B ^a   Wieling, Wouter ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Midodrine; Quality of life; Treatment; Vasovagal syncope

Indexed keywords

MIDODRINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLD SENSATION; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SYNCOPE;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; FLUID THERAPY; HUMANS; MALE; MIDDLE AGED; MIDODRINE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RECURRENCE; SYNCOPE, VASOVAGAL; TREATMENT OUTCOME;

EID: 80054879068     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur200     Document Type: Article

References (38)

1. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB et al. Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009;30:2631-71.
2. Benditt DG, Nguyen JT. Syncope: Therapeutic approaches. J Am Coll Cardiol 2009; 53:1741-51.
3. WielingW, Colman N, Krediet CT, Freeman R. Nonpharmacological treatment of reflex syncope. Clin Auton Res 2004;14(Suppl 1):62-70.
4. Van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A et al. Effectiveness of physical counterpressure manoeuvers in preventing vasovagal syncope: The Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol 2006;48:1652-7. (Pubitemid 44528184)
5. Kaufmann H, Freeman R. Pharmacological treatment of reflex syncope. Clin Auton Res 2004;14(Suppl 1):71-5.
6. Kuriachan V, Sheldon RS, Platonov M. Evidence-based treatment for vasovagal syncope. Heart Rhythm 2008;5:1609-14.
7. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: A double-blind, randomized, crossover study. Ann Neurol 2002;52:342-5. (Pubitemid 35001501)
8. Liao Y, Li X, Zhang Y, Chen S, Tang C, Du J. Alpha-adrenoceptor agonists for the treatment of vasovagal syncope: A meta-analysis of worldwide published data. Acta Paediatr 2009;98:1194-200.
9. Qingyou Z, Junbao D, Chaoshu T. The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope. J Pediatr 2006;149:777-80. (Pubitemid 44816338)
10. Perez-Lugones A, Schweikert R, Pavia S, Sra J, Akhtar M, Jaeger F et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: A randomized control study. J Cardiovasc Electrophysiol 2001;12:935-8. (Pubitemid 32751906)
11. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: A role in the management of neurocardiogenic syncope. Heart 1998;79:45-9. (Pubitemid 28179062)
12. Romme JJCM, Reitsma JB, Go-Schon IK, Harms MPM, Ruiter JH, Luitse JSK et al. Prospective evaluation of non-pharmacological treatment in vasovagal syncope. Europace 2010;12:567-73.
13. Hoefnagels WA, Padberg GW, Overweg J, Van der Velde EA, Roos RA. Transient loss of consciousness: The value of the history for distinguishing seizure from syncope. J Neurol 1991;238:39-43.
14. Brignole M, Alboni P, Benditt DG, Bergfeldt L, Blanc JJ, Bloch Thomsen PE et al. Guidelines on management (diagnosis and treatment) of syncope-update 2004. Europace 2004;6:467-537. (Pubitemid 40378696)
15. McClellan KJ, Wiseman LR, Wilde MI. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. Drugs Aging 1998;12:76-86.
16. Van Dijk N, Sprangers MA, Colman N, Boer KR, Wieling W, Linzer M. Clinical factors associated with quality of life in patients with transient loss of consciousness. J Cardiovasc Electrophysiol 2006;17:998-1003.
17. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993.
18. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-68. (Pubitemid 28527161)
19. Linzer M, Gold DT, Pontinen M, Divine GW, Felder A, Brooks WB. Recurrent syncope as a chronic disease: Preliminary validation of a disease-specific measure of functional impairment. J Gen Intern Med 1994;9:181-6. (Pubitemid 24126155)
20. Van Dijk N, Boer KR, Wieling W, Linzer M, Sprangers MA. Reliability, validity and responsiveness of the syncope functional status questionnaire. J Gen Intern Med 2007;22:1280-5. (Pubitemid 47247302)
21. Sheldon R, Rose S, Flanagan P, Koshman ML, Killam S. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation 1996;93:973-81. (Pubitemid 26074835)
22. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998;17:2635-50. (Pubitemid 28510655)
23. Senn SJ. Problems with the two stage analysis of crossover trials. Br J Clin Pharmacol 1991;32:133.
24. Senn S. The AB/BA design with Normal Data (chapter 3). In: Cross-over Trials in Clinical Research. 2nd ed. Chichester: John Wiley & Sons; 2002. p. 35-88.
25. Grubb BP, Karas B, Kosinski D, Boehm K. Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope. J Interv Card Electrophysiol 1999;3:139-43.
26. Klingenheben T, Credner S, Hohnloser SH. Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: Midodrine as second line treatment in patients refractory to beta-blockers. Pacing Clin Electrophysiol 1999;22: 276-81. (Pubitemid 29109268)
27. Kuchinskaia EA, Pevzner AV, Vershuta EV, Al'bitskaia KV, Kheimets GI, Rogoza AN et al. Results of midodrin treatment of vasovagal syncope. Ter Arkh 2004;76:38-41. (Pubitemid 39278687)
28. Mitro P, Trejbal D, Rybar AR. Midodrine hydrochloride in the treatment of vasovagal syncope. Pacing Clin Electrophysiol 1999;22:1620-4.
29. Samniah N, Sakaguchi S, Lurie KG, Iskos D, Benditt DG. Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope. Am J Cardiol 2001;88:A7, 80-A7, 83.
30. Sra J, Maglio C, Biehl M, Dhala A, Blanck Z, Deshpande S et al. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol 1997;8:42-6. (Pubitemid 27081708)
31. D'Antono B, Dupuis G, St-Jean K, Levesque K, Nadeau R, Guerra P et al. Prospective evaluation of psychological distress and psychiatric morbidity in recurrent vasovagal and unexplained syncope. J Psychosom Res 2009;67:213-22.
32. Gracie J, Newton JL, Norton M, Baker C, Freeston M. The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope. Europace 2006;8:636-43. (Pubitemid 44295762)
33. Sheldon RS, Sheldon AG, Serletis A, Connolly SJ, Morillo CA, Klingenheben T et al. Worsening of symptoms before presentation with vasovagal syncope. J Cardiovasc Electrophysiol 2007;18:954-9. (Pubitemid 47339049)
34. Brooks R, Ruskin JN, Powell AC, Newell J, Garan H, McGovern BA. Prospective evaluation of day-to-day reproducibility of upright tilt-table testing in unexplained syncope. Am J Cardiol 1993;71:1289-92. (Pubitemid 23156682)
35. Sheldon R, Splawinski J, Killam S. Reproducibility of isoproterenol tilt-table tests in patients with syncope. Am J Cardiol 1992;69:1300-5.
36. Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, Carne X, Rius T, Mont L et al. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol 1995;25:65-9.
37. Spiegel B, Strickland A, Naliboff BD, Mayer EA, Chang L. Predictors of patientassessed iIlness severity in irritable bowel syndrome. Am J Gastroenterol 2011; 103:2536-43.
38. Lamarre-Cliche M, Souich P, Champlain J, Larochelle P. Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: A prospective, randomized, single-blind, two-period, crossover, placebo-controlled study. Clin Ther 2008;30: 1629-38.